Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.14 EUR
Change Today -0.041 / -3.46%
Volume 0.0
4LS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 1:36 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

athersys inc (4LS) Snapshot

Open
€1.15
Previous Close
€1.18
Day High
€1.19
Day Low
€1.09
52 Week High
03/23/15 - €3.13
52 Week Low
04/17/15 - €0.74
Market Cap
91.7M
Average Volume 10 Days
1.5K
EPS TTM
--
Shares Outstanding
80.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ATHERSYS INC (4LS)

Related News

No related news articles were found.

athersys inc (4LS) Related Businessweek News

No Related Businessweek News Found

athersys inc (4LS) Details

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has completed Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-versus-host disease. It is also developing MultiStem cell therapy for the treatment of acute respiratory distress syndrome. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. In addition, the company is involved in identifying and developing small molecule compounds with potential applications in indications, including obesity; related metabolic conditions, such as diabetes; and neurological indications consisting of schizophrenia. It has license agreement with Chugai Pharmaceutical Co., Ltd. to develop MultiStem cell therapy for ischemic stroke in Japan, as well as collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; and collaboration with Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets produced compound screening and development. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

57 Employees
Last Reported Date: 03/12/15
Founded in 1995

athersys inc (4LS) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $599.8K
President, Chief Operating Officer and Secret...
Total Annual Compensation: $464.5K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $462.0K
Principal Financial Officer and Vice Presiden...
Total Annual Compensation: $283.3K
Executive Vice President of Regenerative Medi...
Total Annual Compensation: $381.6K
Compensation as of Fiscal Year 2014.

athersys inc (4LS) Key Developments

Athersys Inc. to Present Preliminary Results from Its Phase 2 Clinical Trial of its Investigational Biologic Product for the Treatment of Ischemic Stroke

Athersys Inc. is scheduled to present preliminary results from its phase 2 clinical trial of its investigational biologic product for the treatment of ischemic stroke on April 19, 2015. The experimental product in focus is MultiStem, a proprietary stem cell product that is manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. The phase II study of MultiStem for ischemic stroke was initiated in October 2011, and it completed enrollment last December. In this trial, stroke victims were administered MultiStem cells or placebo intravenously one to two days after the stroke had occurred. The primary endpoints for the study include safety over the first seven days following treatment and global stroke recovery at day 90, which assesses global disability (modified Rankin Score), neurological deficit (NIH stroke scale) and activities of daily living (Barthel Index). In addition to ischemic strokes, MultiStem is being explored in a range of indications like acute myocardial infarction, graft-versus-host disease and ulcerative colitis, to name a few. The company plans to launch phase 2 clinical studies of MultiStem in acute myocardial infarction and acute respiratory distress syndrome this year. The clinical trial results are capable of making or breaking the biotech stocks, and it remains to be seen how the MultiStem trial in ischemic stroke patients pans out.

Athersys, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Athersys, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, total revenues were $0.2 million compared to $0.9 million for the same period in 2013, reflecting a decrease in contract revenues and grant revenue. Net loss was $6.6 million, compared to $9.8 million for the same period of 2013. The difference reflects the impact of a $4.2 million positive variance in the fair value of warrant liabilities, the $0.7 million decrease in revenues, the $0.5 million increase in research and development expenses, and a $0.2 million increase in income tax benefits related to refundable foreign tax credits. Loss from operations was $7.1 million against $5.8 million a year ago. Loss before income taxes was $6.8 million against $9.8 million a year ago. Basic and diluted net loss per share was $0.08 against $0.15 a year ago. For the year, total revenues were $1.6 million compared to $2.4 million for 2013, reflecting a $0.5 million decrease in contract revenues and a $0.3 million decrease in grant revenues. Net loss was $22.1 million, compared to $30.7 million in 2013. The difference reflects a $12.9 million non-cash increase in the change in the fair value of warrant liabilities, the $0.8 million decrease in revenues, the $3.7 million increase in combined research and development and general and administrative expenses, and a $0.2 million increase in income tax benefits related to refundable foreign tax credits. Cash used in operating activities was $25.8 million and $22.8 million in 2014 and 2013, respectively. Loss from operations was $29.0 million against $24.5 million a year ago. Loss before income taxes was $22.3 million against $30.7 million a year ago. Diluted net loss per share was $0.31 against basic and diluted net loss per share of $0.53 a year ago.

Athersys, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 01:00 PM

Athersys, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 01:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4LS:GR €1.14 EUR -0.041

4LS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.0065 USD -0.0002
Biorestorative Therapies Inc $0.39 USD -0.01
Cytori Therapeutics Inc $0.92 USD -0.069
NeoStem Inc $2.91 USD +0.0032
StemCells Inc $0.61 USD +0.0009
View Industry Companies
 

Industry Analysis

4LS

Industry Average

Valuation 4LS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 61.6x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATHERSYS INC, please visit www.athersys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.